Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
As our understanding of the pathophysiology of spinal cord injury deepens, novel neuroprotective agents are being developed, some of which have already entered clinical trials. In this Viewpoint, Sipski and Pearse examine the status of translational research in this field, focusing specifically on issues surrounding the concurrent use of methylprednisolone. The authors also discuss other potential confounders of clinical trials for spinal cord injury and suggest possible solutions.
Although adult mammalian peripheral axons are able to regenerate after injury, this does not always translate into successful functional recovery after nerve injury in humans. In this review, Ahmet Höke considers the cellular and molecular factors that limit peripheral nerve regeneration in humans, and discusses how new animal models might be developed to investigate these barriers to regeneration and to test novel therapeutic approaches.
Sporadic inclusion body myositis is a slowly progressive inflammatory myopathy that is characterized histopathologically by a combination of degenerative and autoimmune inflammatory features in the muscle fibers. In this review, Marinos Dalakas describes the clinical features of sporadic inclusion body myositis, and considers potential disease mechanisms and therapeutic strategies.
Cerebral metastases are a common complication of systemic cancer, and their incidence is set to increase as cancer therapies improve and patients survive longer. In this article, Cavaliere and Schiff review the available therapeutic options for cerebral metastases, and consider the factors that are most likely to influence treatment decisions.